Core Insights - Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖) has successfully transitioned from a pre-profit biotech firm to a profitable entity, achieving a net profit of 546 million yuan in 2023 and a 50.3% year-on-year growth to 820 million yuan in 2024, marking it as the first company to achieve full profitability under the Hong Kong Stock Exchange's Chapter 18A for pre-profit biotech firms [1][3][6] Group 1: Business Strategy - The company has adopted a differentiated and global strategy, rapidly commercializing its innovative products and establishing a significant presence in the global market [1][3] - Junshi's innovative drug, Hanshu, has become the first and only product in the EU to potentially secure a market exclusivity period of up to 10 years [1][6] - The company has successfully launched four products in over 50 countries, reaching 750,000 patients by the end of 2024 [1][8] Group 2: R&D and Innovation - Junshi has focused on high-risk, differentiated indications for drug development, targeting less crowded markets such as small cell lung cancer and gastric cancer [5][6] - The company is advancing its PD-L1 targeted antibody-drug conjugate (ADC) project, HLX43, which is the second globally to enter clinical trials, exploring efficacy against five solid tumors [4][5] - AI technology is being utilized to shorten R&D timelines and reduce costs, with successful projects including the development of a second-generation hyaluronidase [7][8] Group 3: Global Expansion - Junshi has submitted 25 registration applications globally in 2024, receiving 17 approvals across various regions including China and the US [6][8] - The company has established a strong international presence, with a focus on markets in the US, EU, Japan, Southeast Asia, the Middle East, and Latin America [6][8] - Collaborations with global partners such as Abbott and Dr. Reddy's are being pursued to enhance early pipeline development and create a collaborative ecosystem [7][8]
公司零距离•新经济 新动能 | 复宏汉霖：勇闯“无人区”